An interventional study of MB-1 and Placebo in Obese, Overweight Adults and Obese Adults, sponsored by Arrae. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Arrae · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 574 studies in Obesity with a site in Canada — 101 open to participants now, 150 under way, 46 of them phase 3. Obesity · Canada.
Among the 574 studies in Obesity with a site in Canada, this one is the 179th largest by planned enrollment of the 479 interventional ones that give a count, is one of 53 that started in 2026, is one of 280 with no phase, reaches primary completion later than 65 of the 149 other live ones, and was the 525th registered.
11,536 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →101 of the 574 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18–80
Pfizer · Sites in Canada, United States
Ages 18+
Alain Dagher · Sites in Canada
Ages 35–55 · Healthy volunteers
Amgen · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
574 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 63 · Phase 3 97 · Phase 4 26
First in 1997; this study’s year is marked. 53 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 73 across the 479 interventional studies, 52 across the 91 observational. Of the 362 that completed or were terminated, 49 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
162 of 574 have an industry lead sponsor. The 10 most frequent:
Arrae is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Arrae has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
46 of the studies in Obesity with a site in Canada that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
Add all 46 to your calendar (.ics) → With an account.
Among the 574 studies in Obesity with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults. The main question it aims to answer is:
What is the difference in change in body weight from baseline at Day 84 between MB-1 and placebo?
Participants will be provided MB-1 or placebo and be assessed for anthropometric measurements, blood pressure, heart rate, and asked to complete appetite and satiety questionnaires and undergo a DEXA scan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females not of , defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been for at least 1 year prior to screening Or,
Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically-approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MB-1 contains African mango seed (Irvingia Gabonensis), Cissus leaf (Cissus quadrangularis) extract, Grains of Paradise (Aframomum melegueta), Bifidobacterium Lactis (B. lactis) B420, Green tea extract (standardized to 92 ± 2.5 % caffeine), Green tea extract (Camellia sinensis), Vitamin B6, and Chromium Picolinate.
Dietary Supplement: MB-1
Placebo contains white rice flour
Other: Placebo
Participants will be instructed to take two capsules every morning with a meal for the duration of the study starting on Day 1 until the day prior to their end of study visit.
Participants will be instructed to take two capsules every morning with a meal for the duration of the study starting on Day 1 until the day prior to their end of study visit.
The difference in change in body weight between MB-1 and placebo
The difference in change in body weight from baseline at Day 84 between MB-1 and placebo
Time frame: Day 0 to 84
The difference in change in body weight between MB-1 and placebo
The difference in change in body weight from baseline at Day 42 between MB-1 and placebo
Time frame: Day 0 to 42
The difference in change in anthropometric measures (waist and hip circumference) between MB-1 and placebo
The difference in change in anthropometric measures (waist and hip circumference) from baseline at Days 42 between MB-1 and placebo
Time frame: Day 0 to 42
The difference in change in anthropometric measures (waist and hip circumference) between MB-1 and placebo
The difference in change in anthropometric measures (waist and hip circumference) from baseline at Day 84 between MB-1 and placebo
Time frame: Day 0 to 84
The difference in change in body composition (fat and muscle mass) between MB-1 and placebo as assessed by Dual-Energy X-Ray Absorption (DEXA)
The difference in change in body composition (fat and muscle mass) from baseline at Day 84 between MB-1 and placebo as assessed by Dual-Energy X-Ray Absorption (DEXA)
Time frame: Day 0 to 84
The difference in change in fasting blood glucose between MB-1 and placebo as assessed by fasting blood glucose
The difference in change in fasting blood glucose from baseline at Day 84 between MB-1 and placebo as assessed by fasting blood glucose
Time frame: Day 0 to 84
The difference in change in lipid profile between MB-1 and placebo
The difference in change in lipid profile: total cholesterol (TC) between MB-1 and placebo
Time frame: Day 0 to 84
The difference in change in lipid profile between MB-1 and placebo
The difference in change in lipid profile: low-density lipoprotein cholesterol (LDL-C between MB-1 and placebo
Time frame: Day 0 to 84
The difference in change in lipid profile between MB-1 and placebo
The difference in change in lipid profile: high-density lipoprotein cholesterol (HDL-C) between MB-1 and placebo
Time frame: Day 0 to 84
The difference in change in lipid profile between MB-1 and placebo
The difference in change in lipid profile: non-HDL-C between MB-1 and placebo
Time frame: Day 0 to 84
The difference in change in lipid profile between MB-1 and placebo
The difference in change in lipid profile: triglycerides (TG) between MB-1 and placebo
Time frame: Day 0 to 84
The difference in change in lipid profile between MB-1 and placebo
The difference in change in lipid profile: TG/HDL-C, TC/HDL-C and LDL-C/HDL-C between MB-1 and placebo
Time frame: Day 0 to 84
The difference in change in ratings of appetite, satiety, and cravings between MB-1 and placebo as assessed by the weekly Appetite, Satiety and Cravings Likert scales.
The difference in change in ratings of appetite, satiety, and cravings between MB-1 and placebo as assessed by the weekly Appetite, Satiety and Cravings Likert scales.
Time frame: Day 0 to 84
The difference in change in ratings of energy between MB-1 and placebo as assessed by the weekly Energy Likert scale.
The difference in change in ratings of energy from baseline at Day 84 between MB-1 and placebo as assessed by the weekly Energy Likert scale.
Time frame: Day 0 to 84
Incidence of post-emergent adverse events (AE)
Incidence of post-emergent adverse events (AE)
Time frame: Day 0 to 84
Clinically relevant changes in heart rate (HR) after supplementation
Clinically relevant changes in heart rate (HR) after supplementation
Time frame: Day 0 to 84
Clinically relevant changes in blood pressure (BP) after supplementation
Clinically relevant changes in blood pressure (BP) after supplementation
Time frame: Day 0 to 84
Clinically relevant changes in liver function
Clinically relevant changes in liver function.
Time frame: Day 0 to 84
Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.
Of 163 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's planned 6 months is below that.
Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jan 2027 → Feb 2027 and completion Jan 2027 → Feb 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arrae